Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 0.64 |
| ▸ | CCR1 | P32246 | 5/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031095 | 0.84 | SIGMAR1 (0.74) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL4032574 | 0.82 | SIGMAR1 (0.77) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL4206613 | 0.80 | SIGMAR1 (0.69) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL4211485 | 0.80 | SIGMAR1 (0.68) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL2214002 | 0.79 | CCR3 (0.62) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2212902 | 0.79 | CCR3 (0.66) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL2213082 | 0.79 | SIGMAR1 (0.76) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL4030905 | 0.78 | CCR3 (0.64) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL2213599 | 0.78 | CCR3 (0.71) | CCR3CCR1SIGMAR1MEN1KMT2A | |
| SCHEMBL18840726 | 0.78 | CCR3 (1.00) | CCR3CCR1SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | CCR3 21/4885CCR1 11/4885SIGMAR1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.